Key statistics
On Monday, Editas Medicine Inc (0IFK:LSE) closed at 2.81, 205.18% above the 52 week low of 0.9201 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 2.81 |
Low | 2.81 |
Bid | -- |
Offer | -- |
Previous close | 2.92 |
Average volume | 49.98k |
---|---|
Shares outstanding | 83.71m |
Free float | 82.28m |
P/E (TTM) | -- |
Market cap | 241.09m USD |
EPS (TTM) | -3.04 USD |
Data delayed at least 20 minutes, as of Jul 14 2025 18:37 BST.
More ▼
Announcements
- Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
- Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
- Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces First Quarter 2025 Results and Business Updates
- Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
- Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
- Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces Chief Financial Officer Transition
- Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
More ▼